Ranbaxy falsified drug data for years — a $500M fine and the end of an Indian pharma giant

Ranbaxy Laboratories was India's largest pharmaceutical company, known for manufacturing affordable generic drugs for global markets. In the mid-2000s, whistleblowers inside the company revealed that Ranbaxy was systematically falsifying data in drug applications to the US FDA. The company's plants manufactured adulterated drugs, retested failed materials to produce acceptable results, and failed to investigate reports of harmful side effects.

Whistleblowers Rajinder Kumar, director of R&D, and Dinesh Thakur, director of Research Information, exposed the fraud. Kumar resigned after the board refused to recall drugs approved using fraudulent testing. Thakur resigned after the company tried to plant pornography on his computer to justify firing him. Their reports prompted the FDA to issue an Import Alert in September 2008, banning drugs from two Ranbaxy plants.

In May 2013, Ranbaxy pleaded guilty to three felony violations of the Federal Food, Drug, and Cosmetic Act and four felony counts of knowingly making false statements to the FDA. The company paid $500 million in fines. CEO Malvinder Mohan Singh was fired in May 2009.

In 2014, Sun Pharmaceutical acquired Ranbaxy for $4 billion, ending its existence as an independent company. In 2016, the Singapore International Court of Arbitration ordered former Ranbaxy shareholders to pay $525 million to Daiichi Sankyo for intentionally misleading the Japanese company during its 2008 acquisition. The scandal became a landmark case for pharmaceutical data integrity and regulatory compliance.

Ranbaxy paid $500M in fines and $525M in arbitration after falsifying drug data, leading to its sale to Sun Pharma.

Ranbaxy's R&D falsified data in FDA applications to get drugs approved faster. The company's quality control was so poor that drugs contained glass particles and human hair.

Whistleblowers exposed the fraud after the company refused to recall adulterated drugs. The FDA issued an Import Alert in 2008, banning two manufacturing plants.

Ranbaxy paid $500 million in fines. The CEO was fired. Former shareholders paid $525 million to Daiichi Sankyo. The company was acquired by Sun Pharma in 2014.

When a drugmaker's R&D falsifies data to get products approved, the regulator is not the only victim. Patients take those drugs.